Anti-VEGF and beyond: Shaping a new generation of anti-angiogenic therapies for cancer

Drug Discovery Today

Volumn 16, Issue 23-24, 2011, Pages 1052-1060

  Bertolini, Francesco ^a   Marighetti, Paola ^a   Martin Padura, Ines ^a   Mancuso, Patrizia ^a   Hu Lowe, Dana D ^b   Shaked, Yuval ^c   D'Onofrio, Alberto ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b PFIZER INC   (United States)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BIOLOGICAL MARKER; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; DRUG APPROVAL; DRUG MECHANISM; HUMAN; NEOPLASM; NONHUMAN; ONCOLOGY; PATIENT SELECTION; PREDICTION; REVIEW; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 82255191693     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.08.007     Document Type: Review

References (74)

1. R.S. Kerbel Tumor angiogenesis New Engl. J. Med. 358 2008 2039 2049 (Pubitemid 351656458)
2. R.K. Jain Biomarkers of response and resistance to antiangiogenic therapy Nat. Rev. Clin. Oncol. 6 2009 327 338
3. A.D. Blann Circulating endothelial cells. Biomarker of vascular disease Thromb. Haemost. 93 2005 228 235 (Pubitemid 40253726)
4. F. Bertolini Molecular and cellular biomarkers for angiogenesis in oncology Drug Discov. Today 12 2007 806 812 (Pubitemid 47539970)
5. F. Bertolini Cellular and soluble markers of tumor angiogenesis: from patient selection to the identification of the most appropriate post-resistance therapy Biochim. Biophys. Acta Rev. Cancer 1806 2010 131 137
6. G. Bergers, and D. Hanahan Models of resistance to anti-angiogenic therapy Nat. Rev. Oncol. 8 2008 592 603
7. S. Dellapasqua Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer: clinical and biological activity J. Clin. Oncol. 26 2008 4899 4905
8. A. Calleri Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus bevacizumab Clin. Cancer Res. 15 2009 7652 7657
9. A. Grothey Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE) J. Clin. Oncol. 26 2008 5326 5334
10. B.J. Giantonio Targeted therapies: Goldie-Coldman and bevacizumab beyond clinical progression Nat. Rev. Clin. Oncol. 6 2009 211 212
11. Y. Shaked, and E.E. Voest Bone marrow derived cells in angiogenesis and tumor growth: are they the good, the bad or the evil? Biochim. Biophys. Acta Rev. Cancer 1796 2009 1 4
12. L. Yang Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis Cancer Cell 6 2004 409 421 (Pubitemid 39361441)
13. F. Shojaei Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells Nat. Biotechnol. 25 2007 911 920 (Pubitemid 47236916)
14. F. Shojaei Bv8 regulates myeloid cell-dependent tumour angiogenesis Nature 450 2007 825 831 (Pubitemid 350231321)
15. F. Shojaei G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models Proc. Natl. Acad. Sci. U.S.A. 106 2009 6742 6747
16. S. Kummar Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements Nat. Rev. Drug Discov. 9 2010 843 856
17. N.S. Azad Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity J. Clin. Oncol. 26 2008 3709 3714
18. D.R. Feldman Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma J. Clin. Oncol. 27 2009 1432 1439
19. B.I. Rini A Phase I study of sunitinib plus bevacizumab in advanced solid tumors Clin. Cancer Res. 15 2009 6277 6283
20. D. Guertin, and D.M. Sabatini Defining the role of mTOR Cancer Cell 12 2007 9 22
21. H. Huynh Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma J. Hepatol. 49 2008 52 60
22. H. Huynh Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer Mol. Cancer Ther. 6 2007 2959 2966 (Pubitemid 350206774)
23. S. Stephan Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer Clin. Cancer Res. 10 2004 6993 7000 (Pubitemid 39383051)
24. J.R. Merchan Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results J. Clin. Oncol. 25 Suppl. 18 2007 5034
25. J.D. Hainsworth Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma J. Clin. Oncol. 28 2010 2131 2136
26. V.A. Miller A randomized, double-blind, placebo-controlled, Phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) J. Clin. Oncol. 27 Suppl. 15 2009 LBA8002
27. H.L. Kindler Final analysis of a randomized Phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC) J. Clin. Oncol. 26 Suppl. 15 2008 4502
28. M. Dickler Phase II trial of erlotinib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), in patients (pts) with metastatic breast cancer (MBC) J. Clin. Oncol. 22 Suppl. 14 2004 2001
29. R.M. Bukowski Randomized Phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer J. Clin. Oncol. 25 2007 4536 4541 (Pubitemid 350035309)
30. J. Massague TGFbeta in Cancer Cell 134 2008 215 230
31. M.J. Goumans TGF-beta signaling in vascular biology and dysfunction Cell Res. 9 2009 116 127
32. L.D. Urness Arteriovenous malformations in mice lacking activin receptor-like kinase-1 Nat. Genet. 26 2000 328 331
33. S.P. Oh Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis Proc. Natl. Acad. Sci. U.S.A. 97 2000 2626 2631 (Pubitemid 30159221)
34. T. Seki Arterial endothelium-specific activin receptor-like kinase 1 expression suggests its role in arterialization and vascular remodeling Circ. Res. 93 2003 682 689 (Pubitemid 37222165)
35. K. Niessen ALK1 signaling regulates early postnatal lymphatic vessel development Blood 115 2009 1654 1661
36. D.A. Marchuk Vascular morphogenesis: tales of two syndromes Hum. Mol. Genet. 12 2003 97 112
37. H. Sadick Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression Haematologica 90 2005 818 828
38. M.J. Goumans Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling Mol. Cell. 12 2003 817 828
39. S. Lamouille Activin receptor-like kinase 1 is implicated in the maturation phase of angiogenesis Blood 100 2002 4495 4501 (Pubitemid 35429690)
40. C. Mallet TGFbeta1 induces vasculogenesis and inhibits angiogenic sprouting in an embryonic stem cell differentiation model: respective contribution of ALK1 and ALK5 Stem Cells 24 2006 2420 2427 (Pubitemid 44674302)
41. L. David Activin receptor-like kinase 1 inhibits human microvascular endothelial cell migration: potential roles for JNK and ERK J. Cell. Physiol. 213 2007 484 489 (Pubitemid 47509730)
42. E.S. Shao Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells Blood 114 2009 2197 2206
43. M. Scharpfenecker BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis J. Cell Sci. 120 2007 964 972 (Pubitemid 46638511)
44. D.D. Hu-Lowe Targeting ALK1 kinase inhibits angiogenesis and tumor growth through a mechanism of action complementary to anti-VEGF therapies Cancer Res. 71 2011 1362 1373
45. K. Niessen Alk1 signaling regulates early postnatal lymphatic vessel development Blood 115 2010 1654 1661
46. S.I. Cunha Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis J. Exp. Med. 207 2010 85 100
47. W.G. Kaelin Jr, and P.J. Ratcliffe Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway Mol. Cell. 30 2008 393 402 (Pubitemid 351681994)
48. M. Mazzone Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization Cell 136 2009 839 851
49. P. Fraisl Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease Nat. Rev. Drug Discov. 8 2009 139 152
50. M.A. McDonough Selective inhibition of factor inhibiting hypoxia-inducible factor J. Am. Chem. Soc. 127 2005 7680 7681 (Pubitemid 40745948)
51. S. Barth The peptidyl prolyl cis/trans isomerase FKBP38 determines hypoxia-inducible transcription factor prolyl-4-hydroxylase PHD2 protein stability Mol. Cell. Biol. 27 2007 3758 3768 (Pubitemid 46726183)
52. C. Willam Peptide blockade of HIF-1 degradation modulates cellular metabolism and angiogenesis Proc. Natl. Acad. Sci. U.S.A. 99 2002 10423 10428
53. A. Rapisarda Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition Mol. Cancer Ther. 8 2009 1867 1877
54. V. Knights De-regulated FGF receptors as therapeutic targets in cancer Pharmacol. Ther. 125 2010 105 117
55. N. Turner, and R. Grose Fibroblast growth factor signalling: from development to cancer Nat. Rev. Cancer 10 2010 116 129
56. M. Katoh Genetic alterations of FGF receptors: an emerging field in clinical cancer diagnostics and therapeutics Expert Rev. Anticancer Ther. 10 2010 1375 1379
57. E.M. Haugsten Roles of fibroblast growth factor receptors in carcinogenesis Mol. Cancer Res. 8 2010 1439 1452
58. F. Hilberg BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy Cancer Res. 68 2008 4774 4782
59. D. Sarker A Phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors Clin. Cancer Res. 14 2008 2075 2081 (Pubitemid 351551118)
60. J. Matsui E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition Int. J. Cancer 122 2008 664 671 (Pubitemid 350308963)
61. S. Machida Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU-68) Int. J. Cancer 114 2005 224 229
62. H.D. Sun Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys Am. J. Physiol. Endocrinol. Metab. 292 2007 964 976
63. S. Trudel The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells Blood 107 2006 4039 4046 (Pubitemid 43726812)
64. D.J. Dumont Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo Genes Dev. 8 1994 1897 1909 (Pubitemid 24273890)
65. G.D. Gale, and N.W. Yancopoulos Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development Genes Dev. 13 1999 1055 1066
66. D. Hanahan Signaling vascular morphogenesis and maintenance Science 277 1997 48 50 (Pubitemid 27450640)
67. H. Huang Targeting the ANGPT-TIE2 pathway in malignancy Nat. Rev. Cancer 10 2010 575 585
68. J. Oliner Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2 Cancer Cell 6 2004 507 516 (Pubitemid 39469986)
69. J. Neal, and H. Wakelee AMG-386, a selective angiopoietin-1/-2- neutralizing peptibody for the potential treatment of cancer Curr. Opin. Mol. Ther. 12 2010 487 495
70. J.L. Brown A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models Mol. Cancer Ther. 9 2010 145 156
71. S. Van de Veire Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease Cell 141 2010 178 190
72. P. Hahnfeldt Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy Cancer Res. 59 1999 4770 4775 (Pubitemid 29472873)
73. A. D'Onofrio The dynamics of tumour-vasculature interaction suggests low-dose, time-dense anti-angiogenic schedulings Cell Prolif. 42 2009 317 329
74. A.M. Jubb, and A.L. Harris Biomarkers to predict the clinical efficacy of bevacizumab in cancer Lancet Oncol. 11 2010 1172 1183